A Seamless Phase 1b/2a Double-blind, Randomized, Multiple Dose, Multi-center, Sequential Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TB006 in Patients With Mild to Severe Alzheimer's Disease
Latest Information Update: 23 Nov 2023
At a glance
- Drugs TB 006 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors TrueBinding
- 15 Nov 2023 Primary end-points are updated to add 14 new primary end-points for efficacy, safety, pharmacokinetics and a pharmacodynamic (immunogenicity) end-point, thus adding PD as a trial focus. Timelines of previous primary end-points are modified.
- 11 Apr 2023 Status changed from active, no longer recruiting to completed.
- 06 Dec 2022 Results published in a TrueBinding media release.